Overview

Location [1]
3q27.3
Protein [2]
B-cell lymphoma 6 protein
Synonyms [1]
BCL5, BCL6A, ZBTB27, LAZ3, ZNF51

B-cell CLL/lymphoma 6 (BCL6) is a gene that encodes a protein that is a zinc finger transcription factor. The protein functions in transcriptional repression and the regulation of interleukin dependent responses in B-cells. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame deletions are observed in cancers such as esophageal cancer, intestinal cancer, and stomach cancer.

BCL6 is altered in 1.64% of all cancers with lung adenocarcinoma, colon adenocarcinoma, squamous cell lung carcinoma, endometrial endometrioid adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].

BCL6 GENIE Cases - Top Diseases

The most common alterations in BCL6 are BCL6 Amplification (0.40%), BCL6 Fusion (0.13%), BCL6 Loss (0.06%), BCL6-EIF4A2 Fusion (0.10%), and BCL6 R618C (0.03%) [3].

BCL6 GENIE Cases - Top Alterations

Significance of BCL6 in Diseases

Diffuse Large B-Cell Lymphoma +

Double-Hit Lymphoma +

Triple-Hit Lymphoma +

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

Transformed Non-Hodgkin Lymphoma +

High Grade B-Cell Lymphoma, Not Otherwise Specified +

High Grade B-Cell Lymphoma With MYC And BCL2 And/Or BCL6 Rearrangements +

T-Cell/Histiocyte-Rich Large B-Cell Lymphoma +

Grade 3b Follicular Lymphoma +

EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

Primary Mediastinal B-Cell Lymphoma +

Mantle Cell Lymphoma +

Mediastinal Large B-Cell Lymphoma +

Burkitt Lymphoma +

Follicular Lymphoma +

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +

B-Cell Non-Hodgkin Lymphoma +

ALK-Positive Large B-Cell Lymphoma +

Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation +

HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type +

Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma +

Diffuse Large B-Cell Lymphoma Activated B-Cell Type +

Intravascular Large B-Cell Lymphoma +

Marginal Zone Lymphoma +

Non-Hodgkin Lymphoma +

Richter Syndrome +

Hodgkin Lymphoma +

Burkitt Leukemia +

Waldenstrom Macroglobulinemia +

Multiple Myeloma +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Acute Lymphoblastic Leukemia +

Angioimmunoblastic T-Cell Lymphoma +

Chronic Lymphocytic Leukemia +

Follicular T-Cell Lymphoma +

Lymphomatoid Granulomatosis +

Mature B-Cell Lymphoma/Leukemia +

Peripheral T-Cell Lymphoma +

Primary Central Nervous System Lymphoma +

Mature B-Cell Non-Hodgkin Lymphoma +

Indolent Non-Hodgkin Lymphoma +

Hematopoietic And Lymphoid Malignancy +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Acute Myeloid Leukemia +

Anaplastic Large Cell Lymphoma +

Atypical Burkitt/Burkitt-Like Lymphoma +

B-Cell Acute Lymphoblastic Leukemia +

Composite Lymphoma +

EBV-Positive Mucocutaneous Ulcer +

Extranodal Marginal Zone Lymphoma Of Mucosa-Associated Lymphoid Tissue +

Grade 1 Follicular Lymphoma +

Grade 2 Follicular Lymphoma +

Grade 3 Follicular Lymphoma +

Large B-Cell Lymphoma With IRF4 Rearrangement +

Lymphoplasmacytic Lymphoma +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Nodal Marginal Zone Lymphoma +

Nodal Peripheral T-Cell Lymphoma With TFH Phenotype +

Plasma Cell Leukemia +

Plasmablastic Lymphoma +

Primary Effusion Lymphoma +

Splenic Marginal Zone Lymphoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.